Scientific article for healthcare professionals · 13.11.2026 · B1/M1
PRP and PRF in Facial Aesthetics: Evidence, Differences and Limitations
What controlled studies actually show about skin quality, the periorbital area, acne scars and volume restoration—and where the evidence stops.
Introduction: one abbreviation, different products
PRP and PRF are discussed in facial aesthetic medicine as potential ways to influence aspects of skin quality and recovery after other procedures. However, neither term defines a uniform biological product. Collection tubes, anticoagulants, centrifuge geometry, cell composition, activation and timing vary between studies and devices. The actual manufacturing process is part of the intervention—not an interchangeable technical detail. 1, 2, 3, 4
A positive change on ultrasound or in a satisfaction questionnaire is not automatically a visible, clinically important or lasting rejuvenation effect. In addition, results from laser plus PRP cannot be attributed to PRP alone. The November 2026 review by Ticknor and colleagues judged skin-quality outcomes comparatively better supported than true soft-tissue volume replacement, while emphasising low study quality and standardisation gaps. 5, 42
What are PRP, PRF, injectable PRF and PRF matrix?
Platelet-rich plasma (PRP) is usually separated from anticoagulated blood using one or more centrifugation steps. It remains liquid initially and can subsequently be activated, for example with calcium or thrombin, or clot in contact with tissue. Leukocyte-poor and leukocyte-rich preparations differ substantially in cellular composition and platelet dose. A shared acronym does not establish biological equivalence. 1, 3
Classic platelet-rich fibrin (PRF) is generally prepared without an added anticoagulant. Coagulation produces a fibrin network containing varying amounts of platelets and other cells. Injectable PRF (i-PRF) is obtained before clotting is complete, leaving a limited and protocol-dependent period of fluid handling. PRF matrix (PRFM) is used inconsistently in publications: a solid PRF scaffold, a specially activated fibrin product and heat-treated plasma gel are not interchangeable materials. 1, 2
Platelet-derived mediators such as PDGF, TGF-β and VEGF are biologically interesting, but in-vitro release kinetics alone cannot establish a clinically relevant effect in human skin. PRP and PRF must also be distinguished from polynucleotides, extracellular-vesicle or exosome products, and cell or stem-cell therapies. 7, 42
Preparation, centrifugation and the importance of RCF
RPM specifies the number of revolutions per minute, not the centrifugal force acting on a sample. Relative centrifugal force depends on the radius and on RPM squared. The formula uses the radius in centimetres; using millimetres requires a factor ten times smaller. For example, 3,000 RPM at an 8 cm radius produces approximately 805 ×g. The calculated value does not establish a clinically appropriate protocol.
In a review of 121 human PRF studies, investigators identified 29 protocols and 16 centrifuge models. The review largely concerned oral and maxillofacial applications, not facial aesthetic efficacy, but illustrates serious differences in manufacturing descriptions. Two systems reporting the same RPM or even RCF can still produce different fractions because the rotor, tube surface, anticoagulant, timing and sample collection differ. 2
Scientific reports should provide baseline platelet counts, collection and final volume, absolute platelet dose, leukocyte and erythrocyte content, additives, rotor radius, centrifugation time, activation and time to use. The DEPA classification showed a 25-fold range in calculated platelet dose across 20 preparations. This is not evidence that higher doses inevitably yield better clinical outcomes. 3, 4
How reliable is the overall clinical evidence?
An umbrella review published by Cruciani et al. in 2024 identified 13 systematic reviews based on just 28 distinct primary studies. Eighteen primary studies had no control group; 12 of the 13 reviews were rated low or critically low in methodological confidence. Although a meta-analysis found higher patient satisfaction with PRP as an adjunct, the certainty was limited and this did not quantify PRP monotherapy efficacy for facial wrinkles. 5
A 2025 systematic review covering 20 studies and 514 people reported the most frequent positive findings for skin thickness (80% of studies measuring it) and elasticity (75%). Results for wrinkles (40%), texture (33%), dyschromia and hydration were less consistent. These percentages describe studies showing a finding, not patients benefiting or average effect sizes. 7, 42
A nine-trial meta-analysis including 358 people combined different body sites and co-interventions. One included PRP–nanofat study was subsequently retracted in 2025. The pooled estimates therefore require particular caution pending re-analysis without that study. 6, 44, 45
PRP and PRF used alone: skin texture and fine lines
In a placebo-controlled split-face trial by Alam et al., 27 participants enrolled and 19 were analysed. One cheek received PRP and the other saline. Blinded physician assessments did not identify a significant difference in fine lines or roughness. Participants later reported more favourable texture and wrinkle scores on the PRP side, but the satisfaction difference was not significant. Small samples and discordant outcomes limit inference. 9
A separate randomised split-face study in 18 women applied microneedling to both sides and compared adjunctive PRP with saline. It found no convincing extra benefit for skin laxity, wrinkles or roughness. Such controls matter because needling itself constitutes an active tissue stimulus. 46
Evidence for PRF or i-PRF alone is thinner. An uncontrolled i-PRF study in eleven women and an uncontrolled PRFM study of nasolabial folds reported selected improvements, but cannot distinguish treatment effects from natural variation, expectation or assessment bias. Neither establishes durable volume augmentation. 12, 13
Periorbital skin, pigmentation and dark circles
Dark circles are multifactorial: pigment, visible vessels, thin skin, tear-trough anatomy and shadowing can produce similar appearances but are different study endpoints. Improving pigment does not demonstrate correction of a volume deficit.
A 2025 review of 14 studies found no reliable general superiority of PRP or PRF. A 2026 review of 26 studies reported high subjective satisfaction, modest signals for pigmentation and mixed objective findings for wrinkles and texture. Small samples, different preparations and short follow-up limit confidence. 14, 43
In a 2026 randomised split-face comparison, 24 participants completed follow-up. Most direct comparisons between PRP and PRF were not statistically significant. This is neither an equivalence trial nor evidence of effectiveness relative to untreated skin, because both sides received an active preparation. 15
Atrophic acne scars: microneedling and fractional lasers
For atrophic acne scars, PRP has chiefly been investigated as an adjunct. A 2026 meta-analysis covered 17 studies and 1,111 participants, but the pooled quantitative Goodman–Baron scar-score difference (−2.91 points; 95% CI −4.16 to −1.65) came from only four studies involving 255 people. Combining study totals with endpoint-specific sample sizes would exaggerate precision. 47
Some controlled trials report an incremental benefit of PRP over identical microneedling alone, while others do not. A suitable comparison can estimate the added effect of PRP under that particular protocol, but cannot demonstrate the same effect when PRP is given alone. Reviews of acne-scar trials still identify heterogeneity and substantial risk of bias. 17, 18, 19, 20
For fractional CO₂ laser plus PRP, a 2026 meta-analysis included seven randomised trials with 165 people. Selected improvement and satisfaction endpoints favoured the combination, often on the basis of only two trials. No consistent significant differences emerged for erythema, oedema or post-inflammatory pigmentation; follow-up reached no more than six months. A larger 2025 network meta-analysis ranked laser plus PRP highly for one ECCA endpoint, but a SUCRA ranking is not a patient success rate. 21, 48
Hyaluronic acid, fat grafting and nanofat
A randomised 93-participant trial of PRP, hyaluronic acid (HA) and their combination reported improvements in selected skin measurements and patient-reported outcomes. It did not establish extra durable filler volume caused by PRP. Studies using different HA formulations or directly mixed dermal fillers cannot be treated as equivalent. 26, 27
In a double-blind, placebo-controlled facial lipofilling trial, adding PRP did not significantly improve measured volume retention. In a randomised split-face PRF/fat-graft study, retention at three months was 37.21% versus 35.20% without PRF, also not significantly different. Conversely, a small twelve-month trial of i-PRF plus fat found more favourable nasolabial-fold scores; it did not directly measure three-dimensional graft-volume retention. These are conflicting and methodologically distinct endpoints, not proof of reliable volumetric benefit. 28, 29, 49
Nanofat preparations themselves differ in tissue composition depending on processing. Controlled evidence isolating the added contribution of PRP or PRF is insufficient. In particular, a retracted under-eye study must not be cited as positive support. 30, 31, 44, 45
Skin quality is not volume augmentation
Thickness, elasticity, hydration, pigmentation and surface texture describe skin properties. Genuine augmentation concerns three-dimensional tissue volume. A temporary post-injection increase can reflect fluid or oedema; histological collagen changes or a thicker dermis do not by themselves establish durable restoration of deeper soft-tissue compartments.
Validated three-dimensional imaging, appropriate controls, pre-specified clinically meaningful outcomes and longer follow-up are needed to demonstrate additional volume. Existing evidence does not support a blanket claim that liquid PRP, i-PRF or PRFM are dependable substitutes for structural fillers. 28, 29, 42
Safety and unanswered questions
Local pain, redness, swelling, bruising and tenderness are commonly reported transient reactions. In combination procedures, the cause cannot always be separated between platelet preparation and needling or laser treatment. Small trials with short follow-up do not reliably capture rare severe events. 5, 14, 32
A systematic review published in June 2026 identified ten cases of visual impairment following PRP injections in seven publications. Four irreversible blindness cases in an older Karam case series are already included within those ten—not additional cases. Published case reports cannot establish incidence, but they show that serious ophthalmic vascular injury is documented, not merely hypothetical. 33, 34
Contamination, infection and handling errors are further concerns. Data remain inadequate to estimate delayed and repeated-treatment risks or the frequency of rare complications across particular devices and techniques. 32
Reporting standards and transferability between devices
A study reporting only a product name and RPM does not adequately describe its intervention. The centrifuge, tube material and surface, anticoagulant, rotor, radius, RCF, runtime, fraction collection, platelet dose, leukocyte content, activation and application interval all matter. PAW and DEPA classifications and the orthopaedic MIBO consensus can improve reporting, but none establishes a validated aesthetic treatment protocol. 2, 3, 4
Results cannot be automatically transferred from one manufacturer's tube, centrifuge or method to another. Nor can evidence about PRP be conflated with findings on polynucleotides, exosomes or stem-cell products. These are distinct interventions with separate regulatory and evidentiary requirements.
Medical-device claims and European regulatory limits
CE marking applies to the stated intended purpose of a particular device; it is not a general approval of PRP or PRF for facial rejuvenation. Depending on intended use, collection tubes or centrifuges may fall under the EU Medical Devices Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR). Relevant national blood and medicinal-product rules must also be considered. A physician-related exemption from a manufacturing authorisation is not necessarily an exemption from all other requirements. 35, 36, 37
The EMA's Committee for Advanced Therapies discussed a specific combination of autologous PRP and mechanically processed nanofat in June 2026. It was intended to treat refractory olfactory dysfunction—not aesthetic facial indications—and was classified as a tissue-engineered product. The EMA explicitly stated that this decision did not predetermine the classification of autologous PRP used alone. It must not be generalised to every PRP–nanofat combination. 38, 39, 40, 50
The EU SoHO Regulation (EU) 2024/1938 will generally apply from 7 August 2027. Any efficacy claim for a particular product must also respect its documented intended purpose and applicable rules against misleading advertising. 41
Conclusion for medical professionals
The clinical literature suggests that some measurable aspects of skin quality may change after PRP or PRF treatment. For acne scars, selected controlled studies support a possible added effect alongside microneedling or fractional lasers. These findings remain limited by small samples, heterogeneous preparations, variable endpoints and short follow-up. They cannot be assumed to apply to PRP monotherapy.
There is no reliable evidence of lasting independent volume restoration or general superiority of PRF over PRP. Clinically relevant change, laboratory biomarkers and patient satisfaction should be reported separately. Publication claims should identify the precise preparation and comparison group rather than treating “PRP” or “PRF” as a single standardised treatment. 5, 21, 28, 42
Evidence at a glance
| Application | Evidence base | Assessment | Main limitation |
|---|---|---|---|
| General facial skin quality | Small controlled trials and reviews | Low: potential changes in selected parameters | Mixed protocols and short follow-up |
| Skin thickness and elasticity | 2025 systematic review, 20 studies / 514 participants | Low: relatively consistent signals | Clinical importance remains uncertain |
| Fine wrinkles and texture | Split-face trials and systematic reviews | Low to very low: inconsistent findings | Patient and blinded assessor ratings may diverge |
| Periorbital changes / dark circles | 2025 and 2026 reviews; small controlled studies | Low: no reliable overall superiority of PRP or PRF | Different causes of pigmentation and shadows |
| Atrophic acne scars + microneedling | 2026 meta-analysis of 17 studies | Low: possible incremental improvement | Pooled endpoints often draw on fewer patients |
| Acne scars + fractional CO₂ laser | Seven randomised trials; n=165 | Low: possible short-term added benefit | Some estimates based on only two studies |
| PRP with HA or autologous fat | Small randomised and observational studies | Low to very low: no established extra volume retention | Filler and graft effects cannot always be isolated |
| Persistent volume augmentation by PRP/PRF alone | No robust long-term controlled volumetry | Insufficient evidence | Skin thickness is not tissue volume |
The ratings are editorial summaries and are not formal GRADE recommendations. Review populations overlap; do not add them together.
Scientific references
Direct links to journal articles, PubMed, DOI records and regulatory authorities. The original publication titles are retained.
Show the full reference list (51 sources)
- [1] Dohan Ehrenfest DM et al. Classification of platelet concentrates (PRP, PRF) for topical and infiltrative use: current consensus, clinical implications and perspectives. 2014.
- [2] Herrera-Vizcaino C. Systematic review of platelet-rich fibrin centrifugation protocols in oral and maxillofacial surgery and the introduction of AR²T³. 2023.
- [3] Magalon J et al. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. 2016.
- [4] Murray IR et al. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. 2017.
- [5] Cruciani M et al. Platelet rich plasma for facial rejuvenation: an overview of systematic reviews. Blood Transfus. 2024;22(5):429–439.
- [6] Chen H, Zhou X. Meta-Analysis of the Efficacy of Platelet-Rich Plasma in Treating Skin Aging. Aesthet Surg J Open Forum. 2026;8.
- [7] Maisel-Campbell AL et al. A systematic review of the safety and effectiveness of platelet-rich plasma (PRP) for skin aging. Arch Dermatol Res. 2020;312:301–315.
- [8] Rodríguez-Castro MJ, Cortés-Rodríguez AE. Efficacy of platelet-rich plasma in facial rejuvenation: A systematic review. Enferm Clin (Engl Ed). 2025;35(5):502161.
- [9] Alam M et al. Effect of platelet-rich plasma injection for rejuvenation of photoaged facial skin: a randomized clinical trial. JAMA Dermatol. 2018;154:1447–1452.
- [10] Abuaf OK et al. Histologic evidence of new collagen formulation using platelet rich plasma in skin rejuvenation: a prospective controlled clinical study. Ann Dermatol. 2016;28(6):718–724.
- [11] Umeda M et al. Objective evaluation of platelet-rich plasma mesotherapy on facial skin quality: An interim split-face analysis using an advanced imaging system. Regen Ther. 2025;30:969–976.
- [12] Hassan H, Quinlan DJ, Ghanem A. Injectable platelet-rich fibrin for facial rejuvenation: A prospective, single-center study. J Cosmet Dermatol. 2020.
- [13] Sclafani AP. Platelet-rich fibrin matrix for improvement of deep nasolabial folds. J Cosmet Dermatol. 2010.
- [14] Sollitto CF, Narduzzi M, Wolinsky C. A Systematic Review of Platelet-Rich Plasma Versus Platelet-Rich Fibrin for Periorbital Rejuvenation. J Cosmet Dermatol. 2025;24(11).
- [15] Behrangi E et al. Comparing the Efficacy and Safety of PRP and PRF on Periorbital Skin Quality: A Randomized Split-Face Clinical Trial. J Cosmet Dermatol. 2026;25(6).
- [16] Yousef AE, Mohamed NG, Abdelshafy AS. Platelet-Rich Plasma versus Platelet-Rich Fibrin in the Treatment of Periorbital Dark Circles: A Split Face Comparative Study. Zagazig Univ Med J. 2025;31(11):5601–5616.
- [17] Cruciani M et al. Platelet rich plasma use for treatment of acne scars: an overview of systematic reviews. Blood Transfus. 2024;22(3):226–238.
- [18] Kang C, Lu D. Combined effect of microneedling and platelet-rich plasma for the treatment of acne scars: a meta-analysis. Front Med. 2022;8:788754.
- [19] Gupta M, Barman KD, Sarkar R. A Comparative Study of Microneedling Alone Versus Along with Platelet-Rich Plasma in Acne Scars. J Cutan Aesthet Surg. 2021;14(1):64–71.
- [20] Liu Y, Zhang Z, Zhao J. Minimally invasive interventions for atrophic acne scars: a systematic evidence review and exploratory network meta-analysis. Front Surg. 2026;13:1943995.
- [21] Hu Q et al. Adjunctive Use of Platelet-Rich Plasma With Fractional CO₂ Laser Versus Standalone Laser Therapy for Atrophic Acne Scarring: A Systematic Review and Meta-Analysis. J Cosmet Dermatol. 2026;25(9).
- [22] Lee JW et al. The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split-face trial. Dermatol Surg. 2011;37(7):931–938.
- [23] Faghihi G et al. Efficacy of autologous platelet-rich plasma combined with fractional ablative carbon dioxide resurfacing laser in treatment of facial atrophic acne scars. Indian J Dermatol Venereol Leprol. 2016;82:162–168.
- [24] Gawdat H et al. Comparison of the efficacy of Fractional Radiofrequency Microneedling alone and in combination with platelet-rich plasma in neck rejuvenation. J Cosmet Dermatol. 2022;21(5):2038–2045.
- [25] Chen Z et al. Efficacy of Microneedle Fractional Radiofrequency Combined With Platelet-Rich Plasma for the Treatment of Melasma: A Split-Face, Randomized Trial. J Cosmet Dermatol. 2026;25(2).
- [26] Hersant B et al. Synergistic Effects of Autologous Platelet-Rich Plasma and Hyaluronic Acid Injections on Facial Skin Rejuvenation. Aesthet Surg J. 2021;41(7).
- [27] Lee H, Yoon K, Lee M. Full-face augmentation using Tissuefill mixed with platelet-rich plasma: Q.O.Fill. J Cosmet Laser Ther. 2019;21(3):166–170.
- [28] Willemsen JCN et al. The Addition of Platelet-Rich Plasma to Facial Lipofilling: A Double-Blind, Placebo-Controlled, Randomized Trial. Plast Reconstr Surg. 2018;141(2):331–343.
- [29] Zhang ZX et al. Platelet-rich fibrin in fat grafts for facial lipofilling: a randomized, controlled split-face clinical trial. Front Surg. 2022;9:793439.
- [30] Schipper JAM et al. Supplementation of Facial Fat Grafting to Increase Volume Retention: A Systematic Review. Aesthet Surg J. 2022;42(12).
- [31] Arkoubi AY. A Meta-analytic Review of Platelet-Rich Plasma in Fat Grafting: Enhancing Clinical Outcomes. Indian J Surg. 2026;88:32–47.
- [32] Arita A, Tobita M. Adverse events related to platelet-rich plasma therapy and future issues to be resolved. Regen Ther. 2024;26:496–501.
- [33] Ebrahimzade M et al. Ophthalmic Vascular Occlusion and Blindness After Platelet-Rich Plasma Injections: A Systematic Review. J Cosmet Dermatol. 2026.
- [34] Karam EZ et al. Visual Loss after Platelet-rich Plasma Injection into the Face. Neuroophthalmology. 2020;44(6):371–378.
- [35] U.S. FDA. BK230818 Summary: Dr.PRP. 510(k)-Geräteunterlage, 2023.
- [36] Arzneimittelgesetz, § 4: Begriffsbestimmungen, darunter Blutzubereitungen und Herstellung.
- [37] Arzneimittelgesetz, § 13: Herstellungserlaubnis und Ausnahmen, einschließlich ärztlicher patientenbezogener Herstellung.
- [38] Verordnung (EG) Nr. 1394/2007.
- [39] EMA/CAT. Scientific recommendation on classification of ATMPs: Autologous cells of Stromal Vascular Fraction of adipose tissue. 2012.
- [40] EMA/CAT. Scientific recommendation on classification of ATMPs: Autologous viable adipose-derived regenerative cells. 2019.
- [41] Verordnung (EU) 2024.
- [42] Ticknor I, Given KM, Hausauer A. Platelet-Rich Plasma and Platelet-Based Products in Facial Rejuvenation: State of the Evidence in Skin Quality, Periorbital Aesthetics, and Soft Tissue Augmentation. Dermatol Surg. 2026.
- [43] Tai K et al. Platelet-Rich Plasma and Platelet-Rich Fibrin in Periorbital Esthetics: Systematic Review and Clinical Applications. Facial Plast Surg Clin North Am. 2026;34(3):365–394.
- [44] Retraction notice. The Investigation and Comparison of the Efficacy and Safety of Stromal Vascular Fraction, PRP, and Nd:YAG Laser in Reducing Nanofat-Treated Infraorbital Dark Circles and Wrinkles. Skin Res Technol. 2025;31(11).
- [45] Roohaninasab M et al. The Investigation and Comparison of the Efficacy and Safety of Stromal Vascular Fraction, PRP, and 1064-nm Q-switched Nd:YAG Laser in Reducing Nanofat-Treated Infraorbital Dark Circles and Wrinkles. Skin Res Technol. 2024;30(6).
- [46] Pincelli TP et al. Evaluation of Platelet-rich Plasma and Microneedling for Facial Skin Rejuvenation. Plast Reconstr Surg Glob Open. 2024.
- [47] Afreen et al. Microneedling plus PRP bei atrophen Aknenarben. Arch Dermatol Res. 22.04.2026.
- [48] Wu et al. Network Meta-Analysis of Acne Scar Interventions. 2025.
- [49] Alkerdi K et al. i-PRF as an adjunct to fat grafting for facial lipostructure. Dent Med Probl. 2022.
- [50] EMA/CAT/194644/2026.
- [51] Qin et al. Systematic Review of PRP and PRF in Facial Rejuvenation. Ann Plast Surg. 2025.
For medical professionals only. Scientific information, not a patient-directed advertisement or an individual treatment recommendation. No product-specific efficacy or extension of the manufacturer's intended purpose is implied. Last checked: 13 November 2026.